Malign Hastalıkları n Seyrinde Böbreğin Etkilenmesi ve Kemoterapiye Bağlı ABY

1. Winearls CG. Myeloma Kidney. In: Johnson RJ, Feehally J (Eds), Comprehensive Clinical Nephrology, Mosby 2003, pp 235-243.
2. Merchan J, Eder JP. Chemotherapy and renal insufficiency. UpToDate Version 13.3, www.uptodate.com.
3. Rose BD. Cisplatin-induced acute renal failure. UpToDate Version 13.3, www.uptodate.com.
84
Türk Nefroloji Diyaliz ve Transplantasyon Dergisi /Official Journal of the Turkish Society of Nephrology
Malign
Hastalıkları
n Seyrinde Böbreğin Etkilenmesi ve Kemoterapiye Bağlı ABY £
4. Boesler B, Czock D, Keller F, Griesshammer M, Seufferlein T, Karges W, Rasche FM. Clinical course of haemodialysis patients with malignancies and dose-adjusted chemothe¬rapy. Nephrol Dial Transplant 2005;20(6):1187-91. Epub
2005 Apr 19.
5. Ries F, Klastersky J. Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity. Am J Kidney Dis 1986;8(5):368-79.
6. Vogelzang NJ. Nephrotoxicity from chemotherapy: preventi¬on and management. Oncology (Huntingt) 1991;5(10): 97¬102, 105; disc. 105, 109-11.
7. Ettinger LJ, Gaynon PS, Krailo MD, Ru N, Baum ES, Siegel SE,
Hammond GD. A phase II study of carboplatin in children with recurrent or progressive solid tumors. A report from the Childrens Cancer Group. Cancer 1994;73(4):1297-301.
8. McDonald BR, Kirmani S, Vasquez M, Mehta RL. Acute renal failure associated with the use of intraperitoneal carboplatin: a report of two cases and review of the literature. Am J Med 1991;90(3):386-91.
9. Tscherning C, Rubie H, Chancholle A, Claeyssens S, Robert A, Fabre J, Bouissou F. Recurrent renal salt wasting in a child treated with carboplatin and etoposide. Cancer 1994;73(6): 1761-3.
10. Berghmans T. Hyponatremia related to medical anticancer treatment. Support Care Cancer 1996;4(5):341-50.
11. Jefferson A, Zager AR. Causes of Acute Renal Failure. In: Johnson RJ, Feehally J (Eds), Comprehensive Clinical Neph-
rology, Mosby 2003, pp 235-243.
12. Leibbrandt ME, Wolfgang GH, Metz AL, Ozobia AA, Haskins
JR. Critical subcellular targets of cisplatin and related plati¬num analogs in rat renal proximal tubule cells. Kidney Int
1995;48(3):761-70.
13. Megyesi J, Safirstein RL, Price PM. Induction of p21WAF1/
CIP1/SDI1 in kidney tubule cells affects the course of cispla-tin-induced acute renal failure. J Clin Invest 1998;101(4):777-
82.
14. Ramesh G, Reeves WB. TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxi-
city. J Clin Invest 2002;110(6):835-42.
15. De Jongh FE, Van Veen RN, Veltman SJ, De Wit R, Van der Burg ME, Van den Bent MJ, Planting AS, Graveland WJ, Sto-ter G, Verweij J. Weekly high-dose cisplatin is a feasible tre¬atment option: analysis on prognostic factors for toxicity in
400 patients. Br J Cancer 2003;88(8):1199-206.
16. Jackson AM, Rose BD, Graff LG, Jacobs JB, Schwartz JH, Stra¬uss GM, Yang JP, Rudnick MR, Elfenbein IB, Narins RG.
Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy. Ann Intern Med 1984;
101(1):41-4.
17. Ozols RF, Corden BJ, Jacob J, Wesley MN, Ostchega Y, Yo¬ung RC. High-dose cisplatin in hypertonic saline. Ann Intern
Med 1984;100(1):19-24.
18. Capizzi RL. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects.
Semin Oncol 1999;26(2 Suppl 7):72-81.
19. Howell SB; Pfeifle CL; Wung WE; Olshen RA; Lucas WE; Yon
JL; Green M. Intraperitoneal cisplatin with systemic thiosulfa-
te protection. Ann Intern Med 1982;97(6):845-51.
20. Heyman SN, Spokes K, Egorin MJ, Epstein FH. Glycine redu¬ces early renal parenchymal uptake of cisplatin. Kidney Int
1993;43(6):1226-8.
21. Hansen SW, Groth S, Daugaard G, Rossing N, Rorth M. Long-
term effects on renal function and blood pressure of treat¬ment with cisplatin, vinblastine, and bleomycin in patients
with germ cell cancer. J Clin Oncol 1988;6(11):1728-31.
22. Bode U, Seif SM, Levine AS. Studies on the antidiuretic effect of cyclophosphamide: vasopressin release and sodium excre¬tion. Med Pediatr Oncol 1980;8(3):295-303.
23. Bressler RB, Huston DP. Water intoxication following mode¬rate-dose intravenous cyclophosphamide. Arch Intern Med
1985;145(3):548-9.
24. Price TM, Murgo AJ, Keveney JJ, Miller-Hardy D, Kasprisin DO. Renal failure and hemolytic anemia associated with mi-tomycin C. A case report. Cancer 1985;55(1):51-6.
25. Poch E, Gonzalez-Clemente JM, Torras A, Darnell A, Botey A, Revert L. Silent renal microangiography after mitomycin C
therapy. Am J Nephrol 1990;10(6):514-7.
26. Cantrell JE Jr, Phillips TM, Schein PS. Carcinoma-associated hemolytic-uremic syndrome: a complication of mitomycin C
chemotherapy. J Clin Oncol 1985;3(5):723-34.
27. Snyder HW Jr, Mittelman A, Oral A, Messerschmidt GL, Henry DH, Korec S, Bertram JH, Guthrie TH Jr, Ciavarella D, Wuest D, et al. Treatment of cancer chemotherapy-associated throm-botic thrombocytopenic purpura/hemolytic uremic syndrome by protein A immunoadsorption of plasma. Cancer 1993;
71(5):1882-92.
28. Chang AY, Kuebler JP, Tormey DC, Anderson S, Pandya KJ, Borden EC, Davis TE, Trump DL. Phase II evaluation of a combination of mitomycin C, vincristine, and cisplatin in ad¬vanced non-small cell lung cancer. Cancer 1986;57(1):54-9.
29. Pemetrexed
içi
n reçeteleme bilgisi: www.fda.gov/cder/foi/la-bel/2004/021462lbl.pdf (3/10/05).
30. Garrett CA, Simpson TA. Syndrome of inappropriate antidi-uretic hormone associated with vinorelbine therapy. Ann Pharmacother 1998;32(12):1306-9.
31. Belldegrun A, Webb DE, Austin HA , Steinberg SM, White DE,
Linehan WM, Rosenberg SA. Effects of interleukin-2 on renal function in patients receiving immunotherapy for advanced
cancer. Ann Intern Med 1987;106(6):817-22.
32. Mercatello A, Hadj-Aissa A, Negrier S, Allaouchiche B, Coro-nel B, Tognet E, Bret M, Favrot M, Pozet N, Moskovtchenko JF, et al. Acute renal failure with preserved renal plasma flow induced by cancer immunotherapy. Kidney Int 1991;40(2):
309-14.
33. Guleria AS, Yang JC, Topalian SL, Weber JS, Parkinson DR,
MacFarlane MP, White RL, Steinberg SM, White DE, Einhorn
JH, et al. Renal dysfunction associated with the administrati¬on of high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal carcinoma. J Clin Oncol
1994;12(12):2714-22.
34. Ault BH, Stapleton FB, Gaber L, Martin A, Roy S, Murphy SB.
Acute renal failure during therapy with recombinant human
gamma interferon. N Engl J Med 1988;319(21):1397-400.
35. Yang H, Rosove MH, Figlin RA. Tumor lysis syndrome oc¬curring after the administration of rituximab in lymphoproli-ferative disorders: high-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Am J Hematol 1999; 62(4):
247-50.
36. Jensen M, Winkler U, Manzke O, Diehl V, Engert A. Rapid tu¬mor lysis in a patient with B-cell chronic lymphocytic leuke¬mia and lymphocytosis treated with an anti-CD20 monoclo¬nal antibody (IDEC-C2B8, rituximab). Ann Hematol 1998; 77(1-2):89-91.
Official Journal of the Turkish Society of Nephrology/ Türk Nefroloji Diyaliz ve Transplantasyon Dergisi
85
0 Renal Abnormalities During Malignancies and Chemotherapy Related ARF
37. Rose BD, Negrin RS. Renal failure following hematopoietic cell transplantation. UpToDate Version 13.3, www.uptoda-te.com.
38. Cohen EP. Renal failure after bone-marrow transplantation.
Lancet 2001;357(9249):6-7.
39. Zager RA, O'Quigley J, Zager BK, Alpers CE, Shulman HM, Gamelin LM, Stewart P, Thomas ED. Acute renal failure fol¬lowing bone marrow transplantation: a retrospective study of 272 patients. Am J Kidney Dis 1989;13(3):210-6.
40. Hingorani SR, Guthrie K, Batchelder A, Schoch G, Aboulhosn N, Manchion J, McDonald GB. Acute renal failure after mye-loablative hematopoietic cell transplant: Incidence and risk factors. Kidney Int 2005;67(1):272-7.
41. Zager RA. Acute renal failure in the setting of bone marrow
transplantation. Kidney Int 1994;46(5):1443-58.
42. Parikh CR, McSweeney PA, Korular D, Ecder T, Merouani A, Taylor J, Slat-Vasquez V, Shpall EJ, Jones RB, Bearman SI, Schrier RW. Renal dysfunction in allogeneic hematopoietic
cell transplantation. Kidney Int 2002;62(2):566-73.
43. Parikh CR, Schrier RW, Storer B, Diaconescu R, Sorror ML, Maris MB, Maloney DG, McSweeney P, Storb R, Sandmaier BM. Comparison of ARF after myeloablative and nonmyelo-ablative hematopoietic cell transplantation. Am J Kidney Dis
2005;45(3):502-9.
44. Parikh CR, Sandmaier BM, Storb RF, Blume KG, Sahebi F, Maloney DG, Maris MB, Nieto Y, Edelstein CL, Schrier RW,
McSweeney P. Acute renal failure after nonmyeloablative he-matopoietic cell transplantation. J Am Soc Nephrol 2004; 15(7):1868-76.
45. Parikh CR, McSweeney P, Schrier RW. Acute renal failure inde¬pendently predicts mortality after myeloablative allogeneic he-
matopoietic cell transplant. Kidney Int 2005;67(5):1999-2005.
46. Leblond V, Sutton L, Jacquiaud C, Item C, Sadoun R, Jaudon MC, Raymond F, Jacobs C, Deray G. Evaluation of renal func¬tion in 60 long-term survivors of bone marrow transplantati¬on. J Am Soc Nephrol 1995;6(6):1661-5.